The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study (rhinitis)

Yuzuncu Yıl University

Status and phase: Completed; Phase 4

Conditions: Allergic Rhinitis

Treatments: Drug: Omalizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT06806826

19.12.2018/09

Details and patient eligibility

About

We aimed to evaluate the usability and efficacy of omalizumab in allergic rhinitis and its potential as an alternative treatment option.

Full description

The study was conducted to determine the effectiveness of omalizumab on symptoms in patients diagnosed with allergic rhinitis and to compare it with current medical treatment options.

Enrollment: 50 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Those who gave informed consent and wanted to participate in the study and did not have any additional systemic or nasal diseases were included.

Exclusion criteria

• under 18 years old,
• over 65 years old,
• with systemic comorbidities (diabetes mellitus, hypertension, chronic renal failure, hypothyroidism, etc.)
• patients with rhinosinusitis, nasal polyps, nasal septal deviation, tumors, smoking and nasal surgery, and non-compliant patients were excluded from this study.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

Omalizumab group

Active Comparator group

Description:

Between December 2018 and November 2019, 25 patients with allergic rhinitis and chronic urticaria and 25 patients with allergic rhinitis only were included in the study. Patients with allergic rhinitis and chronic urticaria received Omalizumab (300 mg/month) (Omalizumab group).

Treatment:

Drug: Omalizumab

(Desloratadine group).

Active Comparator group

Description:

patients with allergic rhinitis received Montelukast 10 mg plus Desloratadine 5 mg daily (Desloratadine group).

Treatment:

Drug: Omalizumab